Literature DB >> 18469863

Transgenic expression of E2F3a causes DNA damage leading to ATM-dependent apoptosis.

Q X Paulson1, R V Pusapati, S Hong, R L Weaks, C J Conti, D G Johnson.   

Abstract

Many early stage human tumors display markers of a DNA-damage response (DDR), including ataxia telangiectasia mutated (ATM) kinase activation. This suggests that DNA damage accumulates during the process of carcinogenesis and that the ATM-dependent response to this damage may function to suppress cancer progression. The E2F3a transcription factor plays an important role in regulating cell proliferation and is amplified in a subset of human cancers. Similar to human premalignant lesions, we find activated ATM and other markers of the DDR in the hyperplastic epidermis of transgenic mice expressing E2F3a through a keratin 5 (K5) promoter. Primary keratinocytes from K5 E2F3a transgenic mice contain increased levels of DNA breaks compared to wild-type cells. E2F3a overexpression also induced DNA damage in primary human fibroblasts that was inhibited by blocking DNA replication. The absence of ATM impaired apoptosis induced by E2F3a and treating K5 E2F3a transgenic mice with caffeine, an inhibitor of ATM and Rad3-related (ATR), promoted skin tumor development. These findings demonstrate that the deregulated expression of E2F3a causes DNA damage under physiological conditions and indicate that the ATM-dependent response to this damage is important for the induction of apoptosis and tumor suppression.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18469863     DOI: 10.1038/onc.2008.138

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  9 in total

1.  Large T antigen promotes JC virus replication in G2-arrested cells by inducing ATM- and ATR-mediated G2 checkpoint signaling.

Authors:  Yasuko Orba; Tadaki Suzuki; Yoshinori Makino; Kanako Kubota; Shinya Tanaka; Takashi Kimura; Hirofumi Sawa
Journal:  J Biol Chem       Date:  2009-11-10       Impact factor: 5.157

2.  Cell-cycle restriction limits DNA damage and maintains self-renewal of leukaemia stem cells.

Authors:  Andrea Viale; Francesca De Franco; Annette Orleth; Valeria Cambiaghi; Virginia Giuliani; Daniela Bossi; Chiara Ronchini; Simona Ronzoni; Ivan Muradore; Silvia Monestiroli; Alberto Gobbi; Myriam Alcalay; Saverio Minucci; Pier Giuseppe Pelicci
Journal:  Nature       Date:  2009-01-01       Impact factor: 49.962

3.  Notch signaling regulates late-stage epidermal differentiation and maintains postnatal hair cycle homeostasis.

Authors:  Hsien-Yi Lin; Cheng-Heng Kao; Kurt Ming-Chao Lin; Vesa Kaartinen; Liang-Tung Yang
Journal:  PLoS One       Date:  2011-01-18       Impact factor: 3.240

4.  The genetics of osteosarcoma.

Authors:  Jeff W Martin; Jeremy A Squire; Maria Zielenska
Journal:  Sarcoma       Date:  2012-05-20

5.  Retinoblastoma protein (RB) interacts with E2F3 to control terminal differentiation of Sertoli cells.

Authors:  E Rotgers; A Rivero-Müller; M Nurmio; M Parvinen; F Guillou; I Huhtaniemi; N Kotaja; S Bourguiba-Hachemi; J Toppari
Journal:  Cell Death Dis       Date:  2014-06-05       Impact factor: 8.469

6.  Sp1 phosphorylation by ATM downregulates BER and promotes cell elimination in response to persistent DNA damage.

Authors:  Sally C Fletcher; Claudia P Grou; Arnaud J Legrand; Xin Chen; Kalle Soderstrom; Mattia Poletto; Grigory L Dianov
Journal:  Nucleic Acids Res       Date:  2018-02-28       Impact factor: 16.971

7.  Knockdown of E2F3 Inhibits Proliferation, Migration, and Invasion and Increases Apoptosis in Glioma Cells.

Authors:  Zhi-Gang Shen; Xiao-Zhou Liu; Chang-Xiu Chen; Jing-Min Lu
Journal:  Oncol Res       Date:  2017-03-23       Impact factor: 5.574

8.  Oncoviruses and Pathogenic MicroRNAs in Humans.

Authors:  Yoichi Robertus Fujii
Journal:  Open Virol J       Date:  2009-05-07

9.  Loss of E2F1 Extends Survival and Accelerates Oral Tumor Growth in HPV-Positive Mice.

Authors:  Rong Zhong; John Bechill; Michael T Spiotto
Journal:  Cancers (Basel)       Date:  2015-12-08       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.